Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2006
Annals of Oncology 2006 17(8):1234-1238; doi:10.1093/annonc/mdl120
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1234    most recent
mdl120v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Riedinger, J. M.
Right arrow Articles by Pichon, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riedinger, J. M.
Right arrow Articles by Pichon, M. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

J. M. Riedinger1,*, J. Wafflart2, G. Ricolleau3, N. Eche4, H. Larbre5, J. P. Basuyau6, I. Dalifard7, K. Hacene8 and M. F. Pichon9

1 Laboratoire de Biologie Médicale, Centre GF. Leclerc, Dijon, France; 2 Laboratoire de Radioanalyse, Institut Bergonié, Bordeaux, France; 3 Laboratoire d' Oncobiologie, Centre René Gauducheau, Nantes, France; 4 Laboratoire de Biologie, Institut Claudius Regaud, Toulouse, France; 5 Laboratoire de Biologie Clinique, Institut J Godinot, Reims, France; 6 Laboratoire de Biologie, Centre H Becquerel, Rouen, France; 7 Laboratoire de Radioanalyse, Centre P. Papin, Angers, France; 8 Service de Statistiques Médicales, Centre René Huguenin, Saint-Cloud, France; 9 Laboratoire d'Oncobiologie, Centre René Huguenin, Saint-Cloud, France

* Correspondence to: Dr J. M. Riedinger, Laboratoire de Biologie Médicale, Centre GF Leclerc, 1 rue du Pr Marion, 21034 Dijon cedex, France. Tel: +33 03 80 73 75 10; Fax: +33 03 80 73 75 26; E-mail: jriedinger{at}dijon.fnclcc.fr

Background: CA 125 assays enable treatment-response monitoring in ovarian cancer.

Patients and methods: A multicentric study of CA 125 kinetics under induction chemotherapy was performed in 631 patients. CA 125 half-life was calculated by mono-compartmental logarithmic regression. Nadir CA 125 concentration and time to nadir were also studied. Survival analyses for disease-free survival (DFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models.

Results: For 553 stage IIC–IV patients, 459 (83.0%) relapsed and 444 (80.3%) died from cancer. Median (range) follow up time was 32 months (2–214 months). Median (range) for CA 125 kinetics were: 263 kU/l (5–52000 kU/l) before 1st course, 15.8 days (4.5–417.9 days) for CA 125 half-life, 16 kU/l (3–2610 kU/l) for nadir and 85 days (0–361 days) for time to nadir. Pre-chemotherapy CA 125, its half-life, nadir concentration and time to nadir all had a univariate prognostic value for DFS and OS (P < 0.0001). In Cox models, CA 125 half-life, residual tumour (P < 0.0001 for both), nadir concentration (P = 0.0002) and stage (P = 0.0118) were the most powerful prognostic factors for DFS. For OS, the significant variables were similar, with age ranking last (P = 0.0319).

Conclusion: Among well-established prognostic factors in ovarian cancers, CA 125 half-life and nadir concentration bear a strong and independent prognostic value.

Key words: CA 125, ovarian cancer, survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
Ann. Onc., February 1, 2009; 20(2): 294 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Iwanicki-Caron, F. Di Fiore, I. Roque, E. Astruc, M. Stetiu, A. Duclos, D. Tougeron, S. Saillard, S. Thureau, J. Benichou, et al.
Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer
J. Clin. Oncol., August 1, 2008; 26(22): 3681 - 3686.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, B. R. Hoffman, D. W. Chan, S.-L. Ch'ng, E. Hammond, D. F. Hayes, L. A. Liotta, E. F. Petricoin, M. Schmitt, O. J. Semmes, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements
Clin. Chem., August 1, 2008; 54(8): e1 - e10.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M. L. Hensley, D. R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, et al.
Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission
Clin. Cancer Res., May 1, 2008; 14(9): 2740 - 2748.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Riedinger, F Bonnetain, J. Basuyau, N Eche, H Larbre, I Dalifard, J Wafflart, G Ricolleau, and M. Pichon
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome
Ann. Onc., May 1, 2007; 18(5): 881 - 885.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.